摘要
目的:探讨术前应用TP方案诱导化疗后行同步放化疗治疗晚期子宫颈癌的效果及对远期预后的影响。方法:选取2015年8月-2017年8月本院收治的68例局部晚期子宫颈癌患者为研究对象,按照随机数字表法将其分为对照组(给予同步放化疗)和观察组(给予多西紫杉醇+顺铂方案诱导化疗后行同步放化疗),各34例。观察两组近期疗效、肿瘤标志物、毒性反应及远期预后。结果:观察组有效率和手术率较对照组均更高,差异均有统计学意义(P<0.05)。治疗后,两组SCC-Ag、CA125及CEA水平均降低,且观察组SCC-Ag、CA125及CEA水平均较对照组低,差异均有统计学意义(P<0.05)。观察组毒性反应发生率与对照组比较,差异无统计学意义(P>0.05)。观察组术后2年生存率较对照组高,差异有统计学意义(P<0.05)。结论:术前应用多西紫杉醇+顺铂方案诱导化疗后行同步放化疗治疗晚期子宫颈癌患者可提高治疗效果,增加手术机会,改善肿瘤标志物水平,毒性反应少且能提高生存率。
Objective:To explore the effect of simultaneous radiochemotherapy followed by preoperative TP-induced chemotherapy on patients with advanced cervical cancer and its impact on long-term prognosis.Method:A total of 68 patients with locally advanced cervical cancer admitted to our hospital from August 2015 to August 2017 were selected as study subjects,they were divided into the control group(concurrent chemoradiotherapy)and the observation group(concurrent chemoradiotherapy after Docetaxel+Cisplatin regimen induced chemotherapy)according to the random number table,34 cases in each group.The short-term efficacy,tumor markers,toxicity and long-term prognosis of the two groups were compared.Result:The effective rate and operation rate of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of SCC-Ag,CA125 and CEA in both groups were decreased,the levels of SCC-Ag,CA125 and CEA in the observation group were all lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of toxicity between the observation group and the control group(P>0.05).2-year survival rate in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Preoperative application of Docetaxel+Cisplatin regimen after induction chemotherapy and simultaneous chemoradiation therapy for patients with advanced cervical cancer can improve the treatment effect,increase the chance of surgery,improve the level of tumor markers,have fewer toxic reactions and improve survival rate.
作者
柯柳杨
朱的霞
梁文胜
KE Liuyang;ZHU Dixia;LIANG Wensheng(Guangdong Provincial Agricultural Reclamation Central Hospital,Zhanjiang 524002,China;不详)
出处
《中国医学创新》
CAS
2021年第2期6-10,共5页
Medical Innovation of China
关键词
同步放化疗
多西紫杉醇
顺铂
局部晚期子宫颈癌
Simultaneous radiochemotherapy
Docetaxel
Cisplatin
Locally advanced cervical cancer
